| Literature DB >> 19549601 |
Joakim E Swedberg1, Laura V Nigon, Janet C Reid, Simon J de Veer, Carina M Walpole, Carson R Stephens, Terry P Walsh, Thomas K Takayama, John D Hooper, Judith A Clements, Ashley M Buckle, Jonathan M Harris.
Abstract
Human kallikrein-related peptidase 4 (KLK4/prostase), a trypsin-like serine protease, is a potential target for prostate cancer treatment because of its proteolytic ability to activate many tumorigenic and metastatic pathways including the protease activated receptors (PARs). Currently there are no KLK4-specific small-molecule inhibitors available for therapeutic development. Here we re-engineer the naturally occurring sunflower trypsin inhibitor to selectively block the proteolytic activity of KLK4 and prevent stimulation of PAR activity in a cell-based system. The re-engineered inhibitor was designed using a combination of molecular modeling and sparse matrix substrate screening.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19549601 DOI: 10.1016/j.chembiol.2009.05.008
Source DB: PubMed Journal: Chem Biol ISSN: 1074-5521